Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

All NewsApril 6, 2026

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent